• Description
  • Programmes
  • Contact

Sectors: Health, New technologies, Research

Beneficiaries: Administrations States, Agencies Chambers, Banks, Corporations, Development NGOs, Federations Unions, Investment Funds, Local and Regional authorities, Non-profit organisations, Research centres, Schools, SMEs, Training centres, Universities

Regions: European Union

Category: Call for proposals

References:

To view this information, please connect.

Linkedin:

WE funding – Horizon 2020 – Improve…
Funds for: To improve the drug development process
Main beneficiaries: Legal entities

Responsible: European Commission

Useful:

To view this information, please connect.

Amorce:

Funds for: To improve the drug development process
Main beneficiaries: Legal entities

Priorities and funded actions:

TOPICS
Open
IMI2-2018-15-01: Integrated research platforms enabling patient-centric drug development
IMI2-2018-15-02: Blockchain Enabled Healthcare
IMI2-2018-15-03: Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases
IMI2-2018-15-04: Emerging translational safety technologies and tools for interrogating human immuno-biology
IMI2-2018-15-05: Development and validation of translational platforms in support of synaptopathy drug discovery
IMI2-2018-15-06: Digital endpoints in neurodegenerative and immune-mediated diseases
IMI2-2018-15-07: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
IMI2-2018-15-08: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

For more informations: click here